| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 26 | 2025 | 178 | 8.620 |
Why?
|
| Deep Brain Stimulation | 13 | 2025 | 93 | 5.740 |
Why?
|
| Supranuclear Palsy, Progressive | 15 | 2025 | 29 | 5.240 |
Why?
|
| Subthalamic Nucleus | 6 | 2018 | 23 | 2.420 |
Why?
|
| Parkinsonian Disorders | 6 | 2025 | 22 | 1.540 |
Why?
|
| Multiple System Atrophy | 4 | 2025 | 6 | 1.500 |
Why?
|
| Gait | 3 | 2015 | 85 | 1.220 |
Why?
|
| Deglutition Disorders | 2 | 2022 | 126 | 1.180 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2019 | 23 | 1.070 |
Why?
|
| Dopamine Agents | 2 | 2025 | 32 | 1.050 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 296 | 1.040 |
Why?
|
| Disease Progression | 9 | 2025 | 1561 | 1.020 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2025 | 12 | 0.950 |
Why?
|
| Brain | 13 | 2025 | 2479 | 0.930 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 28 | 0.910 |
Why?
|
| Deglutition | 2 | 2015 | 85 | 0.860 |
Why?
|
| Globus Pallidus | 1 | 2024 | 19 | 0.840 |
Why?
|
| Aged | 30 | 2025 | 20927 | 0.770 |
Why?
|
| Movement Disorders | 1 | 2022 | 45 | 0.750 |
Why?
|
| Male | 40 | 2025 | 45792 | 0.720 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 491 | 0.680 |
Why?
|
| Middle Aged | 28 | 2025 | 28299 | 0.680 |
Why?
|
| Essential Tremor | 1 | 2020 | 6 | 0.660 |
Why?
|
| Implantable Neurostimulators | 1 | 2020 | 12 | 0.660 |
Why?
|
| Humans | 61 | 2025 | 95992 | 0.650 |
Why?
|
| Spinocerebellar Ataxias | 2 | 2024 | 88 | 0.650 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 68 | 0.640 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2020 | 206 | 0.610 |
Why?
|
| Atrophy | 4 | 2025 | 131 | 0.610 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2016 | 37 | 0.580 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 180 | 0.570 |
Why?
|
| Female | 35 | 2025 | 49980 | 0.570 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 190 | 0.560 |
Why?
|
| Health Status Disparities | 1 | 2021 | 221 | 0.560 |
Why?
|
| Antiparkinson Agents | 3 | 2013 | 16 | 0.540 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 318 | 0.520 |
Why?
|
| Tremor | 2 | 2019 | 23 | 0.510 |
Why?
|
| Ataxia | 2 | 2014 | 47 | 0.460 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 492 | 0.460 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2015 | 20 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2025 | 3642 | 0.450 |
Why?
|
| Severity of Illness Index | 6 | 2025 | 1982 | 0.450 |
Why?
|
| tau Proteins | 3 | 2019 | 98 | 0.430 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2003 | 68 | 0.430 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2024 | 1 | 0.420 |
Why?
|
| Glucosylceramidase | 1 | 2024 | 3 | 0.420 |
Why?
|
| Chorea | 1 | 2014 | 14 | 0.410 |
Why?
|
| Methamphetamine | 4 | 2004 | 104 | 0.400 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2014 | 121 | 0.390 |
Why?
|
| Nortropanes | 1 | 2012 | 10 | 0.370 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 27 | 0.370 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 99 | 0.370 |
Why?
|
| Fragile X Syndrome | 1 | 2012 | 17 | 0.360 |
Why?
|
| Iodine Radioisotopes | 1 | 2012 | 138 | 0.360 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2025 | 298 | 0.350 |
Why?
|
| Nerve Tissue Proteins | 4 | 2022 | 516 | 0.350 |
Why?
|
| Neurofilament Proteins | 2 | 2025 | 15 | 0.330 |
Why?
|
| Melatonin | 2 | 2021 | 48 | 0.330 |
Why?
|
| Quality of Life | 2 | 2025 | 1816 | 0.330 |
Why?
|
| Neurons | 4 | 2004 | 1654 | 0.330 |
Why?
|
| Machine Learning | 3 | 2025 | 348 | 0.330 |
Why?
|
| Biomarkers | 5 | 2019 | 1931 | 0.320 |
Why?
|
| Disease Management | 1 | 2012 | 363 | 0.310 |
Why?
|
| Double-Blind Method | 5 | 2019 | 1792 | 0.300 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 8 | 0.300 |
Why?
|
| Treatment Outcome | 8 | 2019 | 9228 | 0.290 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 454 | 0.290 |
Why?
|
| Basal Ganglia Diseases | 1 | 2018 | 9 | 0.290 |
Why?
|
| Dopamine | 4 | 2004 | 283 | 0.280 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 58 | 0.270 |
Why?
|
| Global Health | 1 | 2019 | 214 | 0.260 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 1766 | 0.260 |
Why?
|
| Oligopeptides | 2 | 2017 | 193 | 0.260 |
Why?
|
| Dystonia | 1 | 2017 | 31 | 0.250 |
Why?
|
| Basal Ganglia | 1 | 2016 | 47 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 7224 | 0.250 |
Why?
|
| Drug Utilization | 1 | 2017 | 69 | 0.240 |
Why?
|
| Germany | 3 | 2020 | 81 | 0.240 |
Why?
|
| Wallerian Degeneration | 1 | 2006 | 3 | 0.240 |
Why?
|
| Neurotoxins | 1 | 2006 | 48 | 0.240 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2006 | 49 | 0.230 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1880 | 0.230 |
Why?
|
| Cohort Studies | 7 | 2025 | 3115 | 0.230 |
Why?
|
| Language Disorders | 1 | 2025 | 11 | 0.230 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2025 | 24 | 0.230 |
Why?
|
| Support Vector Machine | 1 | 2025 | 25 | 0.230 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2004 | 5 | 0.220 |
Why?
|
| Serotonin | 1 | 2006 | 219 | 0.220 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2006 | 74 | 0.220 |
Why?
|
| Metallothionein | 1 | 2004 | 13 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 1319 | 0.210 |
Why?
|
| Cocaine | 1 | 2004 | 81 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 2885 | 0.200 |
Why?
|
| Membrane Transport Proteins | 2 | 2002 | 171 | 0.190 |
Why?
|
| Striatonigral Degeneration | 1 | 2022 | 1 | 0.190 |
Why?
|
| Olivopontocerebellar Atrophies | 1 | 2022 | 5 | 0.190 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 615 | 0.190 |
Why?
|
| United States | 7 | 2024 | 7785 | 0.180 |
Why?
|
| Comorbidity | 2 | 2021 | 1017 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 2474 | 0.180 |
Why?
|
| Corpus Striatum | 2 | 2016 | 92 | 0.170 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 1176 | 0.170 |
Why?
|
| Spain | 1 | 2020 | 35 | 0.170 |
Why?
|
| France | 1 | 2020 | 54 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2025 | 10307 | 0.170 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 34 | 0.170 |
Why?
|
| Italy | 1 | 2020 | 113 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 935 | 0.160 |
Why?
|
| Blotting, Northern | 5 | 2004 | 257 | 0.160 |
Why?
|
| Body Temperature | 1 | 2000 | 133 | 0.160 |
Why?
|
| Disulfiram | 1 | 2020 | 8 | 0.160 |
Why?
|
| Electric Countershock | 1 | 2020 | 77 | 0.160 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2020 | 47 | 0.150 |
Why?
|
| Copper | 1 | 2020 | 81 | 0.150 |
Why?
|
| Neurites | 1 | 2019 | 36 | 0.150 |
Why?
|
| Arginine | 1 | 2020 | 144 | 0.150 |
Why?
|
| Interferons | 1 | 2020 | 119 | 0.150 |
Why?
|
| Tauopathies | 1 | 2019 | 15 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 103 | 0.150 |
Why?
|
| Down-Regulation | 4 | 2006 | 526 | 0.140 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 1998 | 9 | 0.140 |
Why?
|
| Models, Animal | 1 | 2019 | 287 | 0.140 |
Why?
|
| RNA Splicing | 1 | 2020 | 159 | 0.140 |
Why?
|
| Alternative Splicing | 1 | 2020 | 220 | 0.140 |
Why?
|
| Estrogens | 1 | 1999 | 202 | 0.140 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2004 | 44 | 0.140 |
Why?
|
| Cerebellum | 1 | 2019 | 253 | 0.140 |
Why?
|
| Formamides | 1 | 1997 | 2 | 0.140 |
Why?
|
| Time Factors | 3 | 2018 | 5593 | 0.140 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 28 | 0.140 |
Why?
|
| Ethidium | 1 | 1997 | 13 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2020 | 198 | 0.140 |
Why?
|
| Cisplatin | 1 | 2020 | 599 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2005 | 701 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 1998 | 114 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2000 | 682 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 398 | 0.130 |
Why?
|
| Valine | 1 | 1997 | 61 | 0.130 |
Why?
|
| Methionine | 1 | 1997 | 68 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 355 | 0.130 |
Why?
|
| Torticollis | 1 | 2016 | 12 | 0.130 |
Why?
|
| Saliva | 1 | 2017 | 128 | 0.130 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 30 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 591 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 644 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2002 | 2059 | 0.120 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 262 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2024 | 2495 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2001 | 1191 | 0.120 |
Why?
|
| Levodopa | 1 | 2015 | 36 | 0.110 |
Why?
|
| Calcium Channels | 1 | 2016 | 183 | 0.110 |
Why?
|
| Neoplasms | 2 | 2021 | 3242 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 655 | 0.110 |
Why?
|
| Barium Sulfate | 1 | 2014 | 41 | 0.110 |
Why?
|
| Animals | 12 | 2020 | 28901 | 0.110 |
Why?
|
| Paraneoplastic Cerebellar Degeneration | 1 | 2014 | 1 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2025 | 4690 | 0.100 |
Why?
|
| Nigeria | 1 | 2024 | 162 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 832 | 0.100 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 66 | 0.100 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 3 | 2002 | 12 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 1021 | 0.100 |
Why?
|
| Myoclonus | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 30 | 0.100 |
Why?
|
| Hypokinesia | 1 | 2012 | 3 | 0.090 |
Why?
|
| Mice | 7 | 2020 | 12525 | 0.090 |
Why?
|
| Amyloid beta-Peptides | 2 | 2017 | 246 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1962 | 0.090 |
Why?
|
| Electron Transport Complex IV | 2 | 2002 | 49 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2014 | 295 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2017 | 477 | 0.090 |
Why?
|
| Young Adult | 2 | 2024 | 7034 | 0.090 |
Why?
|
| Electrodes, Implanted | 1 | 2012 | 222 | 0.080 |
Why?
|
| Adult | 5 | 2024 | 28636 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 1267 | 0.080 |
Why?
|
| alpha-Synuclein | 2 | 2022 | 24 | 0.080 |
Why?
|
| Prognosis | 2 | 2018 | 3993 | 0.080 |
Why?
|
| Austria | 2 | 2019 | 16 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2605 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2004 | 2088 | 0.080 |
Why?
|
| Genotype | 1 | 2024 | 1883 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2385 | 0.070 |
Why?
|
| Rats | 3 | 2006 | 4155 | 0.070 |
Why?
|
| Central Nervous System Agents | 1 | 2017 | 15 | 0.070 |
Why?
|
| Syndrome | 1 | 2018 | 450 | 0.070 |
Why?
|
| Central Nervous System | 1 | 1998 | 153 | 0.070 |
Why?
|
| Australia | 1 | 2017 | 125 | 0.060 |
Why?
|
| Canada | 1 | 2017 | 214 | 0.060 |
Why?
|
| p-Chloroamphetamine | 1 | 2006 | 1 | 0.060 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 2006 | 1 | 0.060 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2006 | 11 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3155 | 0.060 |
Why?
|
| Fenfluramine | 1 | 2006 | 20 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 311 | 0.060 |
Why?
|
| Serotonin Agents | 1 | 2006 | 13 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 2776 | 0.060 |
Why?
|
| Europe | 1 | 2017 | 351 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2001 | 3040 | 0.060 |
Why?
|
| Retinitis Pigmentosa | 1 | 2005 | 37 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2017 | 1156 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 113 | 0.060 |
Why?
|
| Gray Matter | 1 | 2025 | 43 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2018 | 435 | 0.060 |
Why?
|
| Axons | 1 | 2006 | 189 | 0.060 |
Why?
|
| 4-Aminopyridine | 1 | 2024 | 37 | 0.050 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2024 | 24 | 0.050 |
Why?
|
| Base Sequence | 2 | 1999 | 2341 | 0.050 |
Why?
|
| Amphetamine | 1 | 2005 | 102 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 187 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 86 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1753 | 0.050 |
Why?
|
| Mesencephalon | 2 | 2001 | 69 | 0.050 |
Why?
|
| Purkinje Cells | 1 | 2024 | 86 | 0.050 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 188 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2004 | 102 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 548 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 3 | 2003 | 996 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 255 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2017 | 463 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2003 | 522 | 0.050 |
Why?
|
| Autopsy | 1 | 2022 | 127 | 0.050 |
Why?
|
| Membrane Transport Modulators | 1 | 2002 | 2 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2003 | 266 | 0.050 |
Why?
|
| Synaptosomes | 1 | 2002 | 14 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2777 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 17 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 36 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 1014 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1827 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2002 | 126 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 179 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2002 | 297 | 0.040 |
Why?
|
| Gene Library | 1 | 2001 | 134 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 171 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 312 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 647 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 930 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 677 | 0.040 |
Why?
|
| Xenobiotics | 1 | 2001 | 8 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2022 | 281 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2002 | 91 | 0.040 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2000 | 11 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1618 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2001 | 82 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2022 | 504 | 0.040 |
Why?
|
| Transcytosis | 1 | 2020 | 3 | 0.040 |
Why?
|
| Nanomedicine | 1 | 2020 | 16 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 66 | 0.040 |
Why?
|
| Oxides | 1 | 2020 | 44 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1966 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 1533 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1999 | 38 | 0.040 |
Why?
|
| Anisotropy | 1 | 2019 | 65 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 317 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3922 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2004 | 2160 | 0.040 |
Why?
|
| COS Cells | 1 | 1999 | 168 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 299 | 0.040 |
Why?
|
| Temperature | 1 | 2000 | 432 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 750 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 1999 | 281 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 198 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 648 | 0.030 |
Why?
|
| beta Catenin | 1 | 2020 | 266 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 528 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 31 | 0.030 |
Why?
|
| Postural Balance | 1 | 2017 | 53 | 0.030 |
Why?
|
| Cell Survival | 1 | 2020 | 1029 | 0.030 |
Why?
|
| Protein Denaturation | 1 | 1997 | 109 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1997 | 163 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2000 | 401 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 225 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2860 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 548 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 911 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 556 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 72 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 857 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2928 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 465 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1729 | 0.030 |
Why?
|
| Alleles | 1 | 1997 | 1157 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1756 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2020 | 3581 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1267 | 0.020 |
Why?
|
| Benztropine | 1 | 2013 | 4 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1464 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 2575 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 150 | 0.020 |
Why?
|
| RNA Probes | 1 | 1998 | 16 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2013 | 827 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1998 | 285 | 0.020 |
Why?
|
| Exons | 1 | 1998 | 454 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2005 | 1 | 0.010 |
Why?
|
| Rod Cell Outer Segment | 1 | 2005 | 2 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 25 | 0.010 |
Why?
|
| Saimiri | 1 | 2005 | 50 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2005 | 48 | 0.010 |
Why?
|
| Papio | 1 | 2005 | 87 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 232 | 0.010 |
Why?
|
| Eye Proteins | 1 | 2005 | 130 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2003 | 18 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 108 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 75 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 128 | 0.010 |
Why?
|
| Response Elements | 1 | 2003 | 65 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 446 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 796 | 0.010 |
Why?
|
| Genes, Synthetic | 1 | 2001 | 7 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 46 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2001 | 45 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 87 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 563 | 0.010 |
Why?
|
| Cysteine Dioxygenase | 1 | 2001 | 1 | 0.010 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2001 | 9 | 0.010 |
Why?
|
| Oxygenases | 1 | 2001 | 17 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 394 | 0.010 |
Why?
|
| Methyltransferases | 1 | 2001 | 213 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 1329 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1642 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 4374 | 0.010 |
Why?
|